Searchable abstracts of presentations at key conferences in endocrinology

ea0086p114 | Neuroendocrinology and Pituitary | SFEBES2022

Skull base lymphoma causing hypopituitarism

Shah Preet , Gonzalez Susana

A 69-year-old lady presented to the ophthalmologists in view of a right 6th cranial nerve palsy and headache. Neuroimaging showed a central and right sided base of skull tumour with involvement of multiple cranial nerves (3rd, 4th, 6th). An endoscopic biopsy was inconclusive. She presented to the medical team few days later with drowsiness, lethargy, and her sodium was found to be 117 mmol/l with a potassium of 5.5 mmol/l. Serum osmolality was 267 mOsm/kg, urine osmolality was...

ea0035mte17 | (1) | ECE2014

FGF23 and phosphorus homeostasis: physiology and pathophysiology

Navarro-Gonzalez Juan

The great majority of the phosphorus in the body is found as phosphate (PO4). Phosphate is critical for the maintenance of bone and skeletal integrity, is a necessary component of important biomolecules, such as RNA and DNA, and is central to signal transduction and cell metabolism. The appropriate serum phosphate concentration is maintained based on the endocrine communication between the skeleton, the kidney, and the intestine. The classical view of phosphate regu...

ea0056p177 | Bone ' Osteoporosis | ECE2018

Malignant hypercalcemia induced by denosumab discontinuation in a patient with primary hyperparathyroidism

Camponovo Chiara , Rodriguez Elena Gonzalez

Context: Denosumab, a fully human monoclonal antibody that inactivates receptor activator of nuclear factor k-B ligand (RANKL), is used for osteoporosis treatment because of its potent anti-resorptive properties. Due to its reversible mode of action, bone resorption increases rapidly after its discontinuation and is accompanied by a quick loss of bone mineral density. Spontaneous vertebral fractures at this period have been recognized as secondary to the rebound of bone resorp...

ea0041gp216 | Thyroid - Translational & Clinical (1) | ECE2016

Endocrine toxicities of immune checkpoint inhibitors: a single centre experience

Gonzalez-Rodriguez Elisa , Rodriguez-Abreu Delvys

Introduction: Immune checkpoint inhibitors (ICI) are a new drug generation used for advanced neoplasias. They are monoclonal antibodies which enhance the immune system to combat cancer cells. As a result, immunologic tolerance can be altered and autoimmunity triggered. Toxicities associated to ICIs have been named immune-related adverse events (irAE). ‘Time to resolution’ of endocrine irAEs have not been well described as this term has not been defined in clinical tr...

ea0032p185 | Cardiovascular Endocrinology & Lipid Metabolism | ECE2013

Mechanism of oxytocin-mediated cardiomyocyte protection

Jankowski Marek , Gonzalez-Reyes Araceli , Gutkowska Jolanta

Oxytocin (OT) treatment improves heart functional recovery in rat model of myocardial infarct. We investigated in the H9c2 cell line (cardiomyocytes model), mechanism of OT action in simulated ischemia - reperfusion (sI-R). H9c2 cells were suspended in warm ischemic buffer and placed inside an anoxic chamber for 2 h at 37 °C, then ‘reperfused’ under normal nutrients and oxygen conditions for 2 h. OT presence during ischemia increased cell viability by 9.7±2...

ea0025p4 | Bone | SFEBES2011

Management of hypovitaminosis D in patients with primary hyperparathyroidism

Rathi Manjusha , Gonzalez Susana , Peacey Steve

Epidemiological studies suggest that hypovitaminosis D is common in patients with primary hyperparathyroidism (PHPT). They have higher levels of serum parathyroid hormone (PTH) and markers of bone turnover, and more frequent fractures than vitamin D replete patients. There are concerns that vitamin D repletion in these patients might exacerbate pre-existent hypercalcaemia, although recent literature suggests this is uncommon.We aimed to determine the eff...

ea0022p181 | Clinical case reports and clinical practice | ECE2010

Syndrome of inappropiate antidiuresis hormone associated with multiple sclerosis

Losada Eladio , Bernal Raquel , Boillos Margarita Gonzalez

Syndrome of inappropriate antidiuresis hormone (SIADH) with many disorders of the nervous system have been reported frequently but its association with multiple sclerosis (MS) is extremely rare (only six cases reported in the literature).A 46 years old woman was admitted to our hospital because of hypersomnolence, confusion and visual disturbances. She presented 6 months before a variety of neurological symptoms suggestive of demyelinating disease withou...

ea0009p58 | Growth and development | BES2005

Growth hormone replacement in patients with hypopituitarism and severe growth hormone deficiency

Gonzalez S , Sugunendran S , Atkin S

Objectives: Patients with acquired growth hormone (GH) deficiency secondary to hypopituitarism, have a significant increased risk of cardiovascular events. However, variable data of the effects of GH replacement and its benefits reducing such risk, is available. The aim of this study was to determine the impact of 0.4 milligrams of GH on cardiovascular markers in severe GH deficient adults with hypopituitarism.Methods: A total of 17 patients (10 males an...

ea0007p165 | Neuroendocrinology and behaviour | BES2004

Functional interactions between anosmin-1, heparan sulphate and urokinase-type plasminogen activator and the pathogenesis of X-linked Kallmann's Syndrome

Hu Y , Gonzalez-Martinez D , Bouloux P

Anosmin-1, a protein defective in X-linked Kallmann's syndrome (X-KS), presents a structure comprising a cysteine rich N terminus (CR), a whey acid protein (WAP) domain followed by four fibronectin-like III domains (FnIII); and its function is heparan sulphate (HS) dependent. However, anosmin-1 and HS binding affinity is unknown. Although the WAP domain belongs to a protein family demonstrating serine protease inhibitory activity, the interacting serine protease remains to be ...

ea0056p238 | Calcium & Vitamin D metabolism | ECE2018

Raloxifene has no efficacy in reducing the risk of spontaneous vertebral fractures after denosumab discontinuation

Rodriguez Elena Gonzalez , Stoll Delphine , Lamy Olivier

Introduction: Denosumab reduces bone resorption, increases BMD, and reduces fracture risk. Denosumab discontinuation (DD) induces an increase of B-crosslaps above baseline values for two years, and a decrease of BMD values. This rebound effect is associated with spontaneous clinical vertebral fractures (SCVF) in close to 15% of patients considering a follow-up of 2 years without taking another osteoporosis treatment. Prescribing a bisphosphonate or SERMs at DD would prevent th...